A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 30 Mar 2017 Results published in a FibroGen media release.
    • 27 Mar 2017 Results published in the Nephrology Dialysis Transplantation.
    • 03 Nov 2015 Results will be presented at American Society of Nephrology - Kidney Week 2015, as per FibroGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top